Personalized approach to pharmacotherapy of overactive bladder

Cover Page

Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription Access

Abstract

The article provides an overview of modern approaches to pharmacotherapy of overactive bladder. It has been shown that the choice of drug therapy for overactive bladder should be made taking into account the pathophysiological mechanisms of the development of the disease, the characteristics of its clinical course, as well as the potential risks of developing side effects of treatment. A pathogenetic rationale for the choice of treatment tactics for different categories of patients is presented, including those with a hypersensitive bladder, bladder outlet obstruction, neurological and geriatric patients. The pharmacological properties of the β3-adrenergic receptor agonist mirabegron are described, which provide high efficacy and a favorable safety profile in the treatment of patients with overactive bladder. The practical issues of prescribing mirabegron in various clinical situations are considered.

About the authors

Igor V. Kuzmin

Academician I.P. Pavlov First St. Petersburg State Medical University

Author for correspondence.
Email: kuzminigor@mail.ru
ORCID iD: 0000-0002-7724-7832
SPIN-code: 2684-4070
https://www.1spbgmu.ru/ru/obrazovanie/kafedry/106-glavnaya/3828-igor-valentinovich-kuzmin

MD, Dr. Sci. (Med.), professor of the Department of Urology

Russian Federation, Saint Petersburg

References

  1. Abrams P, Cardozo L, Fall M, et al. The standartisation of terminology in lower urinary tract function: Report from the standartisation sub-committee of the International Continence Society. Neurourol Urodyn. 2002;21(2):167–178. doi: 10.1002/nau.10052
  2. Al-Shukri SK, Kuzmin IV. Quality of life in patients with overactive bladder. Urology reports (St. Petersburg). 2011;1(1):21–26. (In Russ.) doi: 10.17816/uroved57653
  3. Irwin DE, Milsom I, Hunskaar S, et al. Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. Eur Urol. 2006;50(6):1306–1314. doi: 10.1016/j.eururo.2006.09.0193
  4. Kuzmin IV. Patogenez, klinicheskoe techenie i lechenie giperaktivnosti mochevogo puzyrya. [dissertation abstract]. Saint Petersburg; 2007. 40 p. (In Russ.)
  5. Kuzmin IV. Epidemiological aspects of overactive bladder and urge urinary incontinence. Urology reports (St. Petersburg). 2015;5(3):30–34. (In Russ.) doi: 10.17816/uroved5330-34
  6. Peyronnet B, Mironska E, Chapple C, et al. A comprehensive review of overactive bladder pathophysiology: on the way to tailored treatment. Eur Urol. 2019;75(6):988–1000. doi: 10.1016/j.eururo.2019.02.038
  7. Thurmond P, Yang JH, Azadzoi KM. LUTS in pelvic ischemia: a new concept in voiding dysfunction. Am J Physiol Renal Physiol. 2016;310(8):F738–F743. doi: 10.1152/ajprenal.00333.201521
  8. Berdichevsky BA, Berdichevsky VB. Detrusor ischemia. Clinical effects. Urologiia. 2019;(5):132–135. (In Russ.) doi: 10.18565/urology.2019.5.132-135
  9. Pinggera G, Mitterberger M, Steiner E, et al. Association of lower urinary tract symptoms and chronic ischaemia of the lower urinary tract in elderly women and men: assessment using colour Doppler ultrasonography. BJU Int. 2008;102(4):470–474. doi: 10.1111/j.1464-410X.2008.07587.x
  10. Al-Shukri SH, Kuzmin IV, Boriskin AG, et al. Correction of microcirculatory disorders in patients with overactive bladder. Nephrology (Saint Petersburg). 2011;15(1):58–64. (In Russ.)
  11. Lee SR, Kim HJ, Kim A, Kim JH. Overactive bladder is not only overactive but also hypersensitive. Urology. 2010;75(5):1053–1059. doi: 10.1016/j.urology.2009.10.045
  12. Kushida N, Fry CH. On the origin of spontaneous activity in the bladder. BJU Int. 2016;117(6):982–992. doi: 10.1111/bju.13240
  13. Chen SL, Ng SC, Huang YH, Chen GD. Are patients with bladder oversensitivity different from those with urodynamically proven detrusor overactivity in female overactive bladder syndrome? J Chin Med Assoc. 2017;80(10):644–650. doi: 10.1016/j.jcma.2017.03.009
  14. Roosen A, Chapple CR, Dmochowski RR, et al. A refocus on the bladder as the originator of storage lower urinary tract symptoms: a systematic review of the latest literature. Eur Urol. 2009;56(5): 810–819. doi: 10.1016/j.eururo.2009.07.044
  15. Kaplan SA, Dmochowski R, Cash BD, et al. Systematic review of the relationship between bladder and bowel function: implications for patient management. Int J Clin Pract. 2013;67(3):205–216. doi: 10.1111/ijcp.12028
  16. Bunn F, Kirby M, Pinkney E, et al. Is there a link between overactive bladder and the metabolic syndrome in women? A systematic review of observational studies. Int J Clin Pract. 2015;69:199–217. doi: 10.1111/ijcp.12518
  17. Vrijens D, Drossaerts J, van Koeveringe G, et al. Affective symptoms and the overactive bladder — a systematic review. J Psychosom Res. 2015;78:95–108. doi: 10.1016/j.jpsychores.2014.11.019
  18. Javan Balegh Marand A, Baars C, Heesakkers J, et al. Differences in the urinary microbiome of patients with overactive bladder syndrome with and without detrusor overactivity on urodynamic measurements. Life (Basel). 2023;13(5):1199. doi: 10.3390/life13051199
  19. Hood B, Andersson KE. Common theme for drugs effective in overactive bladder treatment: inhibition of afferent signaling from the bladder. Int J Urol. 2013;20(1):21–27. doi: 10.1111/j.1442-2042.2012.03196.x19
  20. Nederzhanie mochi. Klinicheskie rekomendatsii Minzdrava RF. 2020 [cited: 2023 Sept 02]. Available from: http://cr.rosminzdrav.ru/recomend/8_1
  21. Harding CK, Lapitan MC, Arlandis S, et al. European Association of Urology. Management of non-neurogenic female lower urinary tract symptoms (LUTS). EAU Guideline. 2023 [cited: 2023 Sept 02] Available from: https://uroweb.org/guidelines/non-neurogenic-female-luts
  22. Rai BP, Cody JD, Alhasso A, Stewart L. Anticholinergic drugs versus non-drug active therapies for non-neurogenic overactive bladder syndrome in adults. Cochrane Database Syst Rev. 2012;12(12): CD003193. doi: 10.1002/14651858.CD003193.pub422
  23. Sartori LGF, Nunes BM, Farah D, et al. Mirabegron and anticholinergics in the treatment of overactive bladder syndrome: a meta-analysis. Rev Bras Ginecol Obstet. 2023;45(6):337–346. doi: 10.1055/s-0043-1770093
  24. Alyaev YuG, Gadzhieva ZK. M-kholinoblokatory v lechenii giperaktivnogo mochevogo puzyrya. Effektivnaya Farmakoterapiya. 2010;(29):28–35.
  25. Kasjan GR. Mirabegron — a new drug for treatment of overactive bladder. Urologiia. 2015;(4):121–124. (In Russ.)
  26. Kulchavenya EV, Kholtobin DP. Overactive bladder in a complicated patient: which drug to choose? Urologiia. 2021;(1):120–125. (In Russ.) doi: 10.18565/urology.2021.1.120–125
  27. Kuzmin IV, Kuzmina SV. Anticholinergic therapy of an overactive bladder: clinical practice aspects. Russian Medical Inquiry. 2021;5(5): 273–279 (In Russ.) doi: 10.32364/2587-6821-2021-5-5-273-279
  28. Ehlert FJ, Ahn S, Pak KJ, et al. Neuronally released acetylcholine acts on the M2 muscarinic receptor to oppose the relaxant effect of isoproterenol on cholinergic contractions in mouse urinary bladder. J Pharmacol Exp Ther. 2007;322(2):631–637. doi: 10.1124/jpet.107.121756
  29. Hegde SS. Muscarinic receptors in the bladder: from basic research to therapeutics. Br J Pharmacol. 2006;147(Suppl 2):S80–S87. doi: 10.1038/sj.bjp.0706560
  30. Chapple CR, Dvorak V, Radziszewski P, et al. A phase II dose-ranging study of mirabegron in patients with overactive bladder. Int Urogynecol J. 2013;24(9):1447–1458. doi: 10.1007/s00192-013-2042-x
  31. Nitti VW, Chapple CR, Walters C, et al. Safety and tolerability of the β3-adrenoceptor agonist mirabegron, for the treatment of overactive bladder: Results of a prospective pooled analysis of three 12-week randomised phase III trials and of a 1-year randomised phase III trial. Int J Clin Pract. 2014;68(8):972–985. doi: 10.1111/ijcp.12433
  32. Kanai A, Wyndaele J, Andersson K, et al. Researching bladder afferents-determining the effects of β3-adrenergic receptor agonists and botulinum toxin type-A. Neurourol. Urodyn. 2011;30(5):684–691. doi: 10.1002/nau.21102
  33. Krivoborodov GG, Tur EI, Shirin DA. Hyperactive bladder the concept of disease and paradigms in the treatment. Medical Council. 2021;(4):121–126. (In Russ.) doi: 10.21518/2079-701X-2021-4-121-126
  34. Romikh VV, Zakharchenko AV, Kukushkina LYu, et al. Current concepts of the overactive bladder in women. Strategy for choosing drug therapy. Obstetrics and Gynecology. 2021;(8):183–191. (In Russ.) doi: 10.18565/aig.2021.8.183-191
  35. Kuzmin IV, Al-Shukri SK. Fesoterodine for the treatment of overactive bladder: pharmacological bases and clinical results. Urology Reports (St. Petersburg). 2020;10(2):163–171. (In Russ.) doi: 10.17816/uroved102163-171
  36. Resolution of the expert board on urodynamics and neurourology sections of neurourology of the Russian society of urology (ROU) OCTOBER8, 2022 (SOCHI) Urology. 2022;(6):134–136. doi: 10.18565/urology.2022.6.134-136
  37. Lightner DJ, Gomelsky A, Souter L, Vasavada SP. Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA/SUFU Guideline Amendment 2019. J Urol. 2019;202(3):558–563. doi: 10.1097/JU.000000000000030921
  38. Liao CH, Kuo HC. High satisfaction with direct switching from antimuscarinics to mirabegron in patients receiving stable antimuscarinic treatment. Medicine (Baltimore). 2016;95(45):e4962. doi: 10.1097/MD.0000000000004962
  39. Abrams P, Kelleher C, Staskin D, et al. Combination treatment with mirabegron and solifenacin in patients with overactive bladder: Exploratory responder analyses of efficacy and evaluation of patient-reported outcomes from a randomized, double-blind, factorial, dose-ranging, phase II study (SYMPHONY). World J Urol. 2017;35(5):827–838. doi: 10.1007/s00345-016-1908-1
  40. Apostolidis A, Averbeck MA, Sahai A, et al. Can we create a valid treatment algorithm for patients with drug resistant overactive bladder (OAB) syndrome or detrusor overactivity (DO)? Results from a think tank (ICI-RS2015). Neurourol Urodyn. 2017;36(4):882–893. doi: 10.1002/nau.23170
  41. Kuzmin IV, Slesarevskaya MN, Amdiy RE, et al. Long-term botulinum therapy for overactive bladder: myths and reality. Urology Reports (St. Petersburg). 2022;12(1):71–84 (In Russ.) doi: 10.17816/uroved104335
  42. Lee YS, Choo MS, Lee JY, et al. Symptom change after discontinuation of successful antimuscarinic treatment in patients with overactive bladder symptoms: A randomised, multicentre trial. Int J Clin Pract. 2011;65(9):997–1004. doi: 10.1111/j.1742-1241.2011.02728.x
  43. Shim EJ, Yoo EH, Kim YM, Kim D. Factors affecting medication discontinuation in patients with overactive bladder symptoms. Obstet Gynecol Sci. 2015;58(6):507–513. doi: 10.5468/ogs.2015.58.6.507
  44. Wagg A, Franks B, Ramos B, Berner T. Persistence and adherence with the new beta-3 receptor agonist, mirabegron, versus antimuscarinics in overactive bladder: Early experience in Canada. Can Urol Assoc J. 2015;9(9–10):343–350. doi: 10.5489/cuaj.3098
  45. Chapple CR, Nazir J, Hakimi Z, et al. Persistence and Adherence with mirabegron versus antimuscarinic agents in patients with overactive bladder: a retrospective observational study in UK clinical practice. Eur Urol. 2017;72(3):389–399. doi: 10.1016/j.eururo.2017.01.037
  46. Wang CC, Jiang YH, Ong HL, Kuo HC. Higher urge severity scale predicts the recurrence of overactive bladder symptoms after discontinuing mirabegron in patients with overactive bladder. ICS Abstract. 2017;(479).
  47. Patra PB, Patra S. Sex differences in the physiology and pharmacology of the lower urinary tract. Curr Urol. 2013;6(4):179–188. doi: 10.1159/000343536
  48. Spradling K, Khoyilar C, Abedi G, et al. Redefining the autonomic nerve distribution of the bladder using 3-dimensional image reconstruction. J Urol. 2015;194(6):1661–1667. doi: 10.1016/j.juro.2015.05.077
  49. Sigala S, Mirabella G, Peroni A, et al. Differential gene expression of cholinergic muscarinic receptors subtypes in male and female normal human urinary bladder. Urology. 2002;60(4):719–725. doi: 10.1016/s0090-4295(02)01819-8
  50. Sugaya K, Nishijima S, Kadekawa K, et al. Relation between lower urinary tract symptoms and urinary ATP in patients with benign prostatic hyperplasia or overactibe bladder. Biomed Res. 2009;30(5):287–294. doi: 10.2220/biomedres.30.287
  51. Morita T, Masuda H, Tosaka A, et al. Sex differences in function and distribution of beta-adrenoceptors in rabbit urinary bladder. J Urol. 1998;159:555–558. doi: 10.1016/s0022-5347(01)63982-x
  52. Coyne KS, Sexton CC, Vats V, et al. National community prevalence of overactive bladder in the United States stratified by sex and age. Urology. 2011;77(5):1081–1087. doi: 10.1016/j.urology.2010.08.039
  53. Sekido N, Hinotsu S, Kawai K, et al. How many uncomplicated male and female overactive bladder patients reveal detrusor overactivity during urodynamic study? Int J Urol. 2006;13(10):1276–1279. doi: 10.1111/j.1442-2042.2006.01558.x
  54. Slesarevskaya MN, Ignashov YA, Kuzmin IV, Al-Shukri SK. Persistent dysuria in women: etiological diagnostics and treatment. Urology reports (St. Petersburg). 2021;11(3):195–204 (In Russ.) doi: 10.17816/uroved81948
  55. Al-Ghazo MA, Ghalayini IF, Al-Azab R, et al. Urodynamic detrusor overactivity in patients with overactive bladder symptoms. Int Neurourol J. 2011;15(1):48–54. doi: 10.5213/inj.2011.15.1.48
  56. Blanc F, Pichot V, Roche F, et al. Activity of the autonomous nervous system measured based on the variability of heart rate in female urinary incontinence. Prog Urol. 2001;11(3):492–497. (In French.)
  57. Choi JB, Kim YB, Kim BT, Kim YS. Analysis of heart rate variability in female patients with overactive bladder. Urology. 2005;65: 1109–1112. Discussion 1113. doi: 10.1016/j.urology.2005.01.029
  58. Hubeaux K, Deffieux X, Ismael SS, et al. Autonomic nervous system activity during bladder filling assessed by heart rate variability analysis in women with idiopathic overactive bladder syndrome or stress urinary incontinence. J Urol. 2007;178(6):2483–2487. doi: 10.1016/j.juro.2007.08.036
  59. Hubeaux K, Deffieux X, Raibaut P, et al. Evidence for autonomic nervous system dysfunction in females with idiopathic overactive bladder syndrome. Neurourol Urodyn. 2011;30:1467–1472. doi: 10.1002/nau.21154
  60. Chen YC, Chen HW, Huang TC, et al. Skin sympathetic nerve activity as a potential biomarker for overactive bladder. World J Urol. 2023;41(5):1373–1379. doi: 10.1007/s00345-023-04376-16
  61. Ates E, Ipekci T, Akin Y, et al. Impact of sympathetic dysfunction in the etiology of overactive bladder in women: A preliminary study. Neurourol Urodyn. 2016;35(1):26–28. doi: 10.1002/nau.22652
  62. Hsiao SM, Tu FC, Su TC, et al. Impact of mirabegron versus solifenacin on autonomic function and arterial stiffness in female overactive bladder syndrome: a randomized controlled trial. Sci Rep. 2022;12(1):14219. doi: 10.1038/s41598-022-18391-6
  63. Lua LL, Pathak P, Dandolu V. Comparing anticholinergic persistence and adherence profiles in overactive bladder patients based on gender, obesity, and major anticholinergic agents. Neurourol Urodyn. 2017;36(8):2123–2131. doi: 10.1002/nau.23256
  64. Krhut J, Martan A, Zachoval R, et al. Impact of body mass index on treatment efficacy of mirabegron for overactive bladder in females. Eur J Obstet Gynecol Reprod Biol. 2016;196:64–68. doi: 10.1016/j.ejogrb.2015.11.018
  65. Kallner HK, Elmér C, Andersson KE, Altman D. Hormonal influence on the effect of mirabegron treatment for overactive bladder. Menopause. 2016;23(12):1303–1306. doi: 10.1097/GME.0000000000000708
  66. Oelke M, Baard J, Wijkstra H, et al. Age and bladder outlet obstruction are independently associated with detrusor overactivity in patients with benign prostatic hyperplasia. Eur Urol. 2008;54(2): 419–426. doi: 10.1016/j.eururo.2008.02.017
  67. Kurizaki Y, Ishizuka O, Imamura T, et al. Relation between expression of α(1)-adrenoceptor mRNAs in bladder mucosa and urodynamic findings in men with lower urinary tract symptoms. Scand J Urol Nephrol. 2011;45(1):15–19. doi: 10.3109/00365599.2010.515611
  68. Kurizaki Y, Ishizuka O, Imamura T, et al. Relationship between expression of β3-adrenoceptor mRNA in bladder mucosa and urodynamic findings in men with lower urinary tract symptoms. Neurourol Urodyn. 2013;32(1):88–91. doi: 10.1002/nau.22278
  69. Kim JC, Yoo JS, Park EY, et al. Muscarinic and purinergic receptor expression in urothelium of rats with detrusor overactivity induced by bladder outlet obstruction. BJU Int. 2007;101(3):371–375. doi: 10.1111/j.1464-410X.2007.07251.x
  70. Liao CH, Kuo YC, Kuo HC. Predictors of successful first-line antimuscarinic monotherapy in men with enlarged prostate and predominant storage symptoms. Urology. 2013;81(5):1030–1033. doi: 10.1016/j.urology.2013.01.018
  71. Nitti VW, Rosenberg S, Mitcheson DH, et al. Urodynamics and safety of the β3-adrenoceptor agonist mirabegron in males with lower urinary tract symptoms and bladder outlet obstruction. J Urol. 2013;190(4):1320–1327. doi: 10.1016/j.juro.2013.05.062
  72. Neirogennaya disfunktsiya nizhnikh mochevyvodyashchikh putei. Klinicheskie rekomendatsii Minzdrava RF. 2020 [cited 2023 Sept 12]. Available from: https://cr.minzdrav.gov.ru/schema/588_2.
  73. Haab F. Chapter 1: The conditions of neurogenic detrusor overactivity and overactive bladder. Neurourol Urodyn. 2014;33(Suppl 3): S2–S5. doi: 10.1002/nau.2263
  74. Kuzmin IV. Dysfunctions of the lower urinary tract in patients with multiple sclerosis. Pathogenesis, symptomatics, diagnosis. Urology reports (St. Petersburg). 2023;13(2):145–156. (In Russ.) doi: 10.17816/uroved529654
  75. Mehnert U, Chartier-Kastler E, de Wachter S, et al. The management of urine storage dysfunction in the neurological patient. SN Compr Clin Med. 2019;(1):160–182. doi: 10.1007/s42399-018-0005-8
  76. Tibaek S, Gard G, Klarskov P, et al. Prevalence of lower urinary tract symptoms (LUTS) in stroke patients: a cross-sectional, clinical survey. Neurourol Urodyn. 2008;27(8):763–771. doi: 10.1002/nau.20605
  77. Quarto G, Autorino R, Gallo A, et al. Quality of life in women with multiple sclerosis and overactive bladder syndrome. Int Urogynecol J Pelvic Floor Dysfunct. 2007;18(2):189–194. doi: 10.1007/s00192-006-0131-9
  78. Madersbacher H, Mürtz G, Stöhrer M. Neurogenic detrusor overactivity in adults: a review on efficacy, tolerability and safety of oral antimuscarinics. Spinal Cord. 2013;51(6):432–441. doi: 10.1038/sc.2013.19
  79. Amarenco G, Sutory M, Zachoval R, et al. Solifenacin is effective and well tolerated in patients with neurogenic detrusor overactivity: results from the double-blind, randomized, active- and placebo-controlled SONIC urodynamic study. Neurourol Urodyn. 2017;36(2): 414–421. doi: 10.1002/nau.22945
  80. Blok B, Castro-Diaz D, Del Popolo G, et al; Guideline of European Urological Association. Neuro-Urology. 2023 [cited: 2023 Sept 02]. Available from: https://uroweb.org/guideline/neuro-urology.
  81. Krivoborodov GG, Kuzmin IV, Romikh VV. Аbobotulinum toxin A (Dysport®) for the treatment of neurogenic detrusor overactivity. Urologiia. 2023;2:122–129. (In Russ.) doi: 10.18565/urology.2023.2.122-12
  82. Pontari MA, Braverman AS, Ruggieri MR Jr. The M2 muscarinic receptor mediates in vitro bladder contractions from patients with neurogenic bladder dysfunction. Am J Physiol Regul Integr Comp Physiol. 2004;286(5):R874–R880. doi: 10.1152/ajpregu.00391.2003
  83. Chancellor M, Boone T. Anticholinergics for overactive bladder therapy: central nervous system effects. CNS Neurosci Ther. 2012;18(2):167–174. doi: 10.1111/j.1755-5949.2011.00248.x
  84. Kuzmin IV, Slesarevskaya MN. Anticholinergic bladder therapy: geriatric aspects. Clin Gerontol. 2021;27(11–12):21–34. (In Russ.) doi: 10.26347/1607-2499202111-12021-034
  85. Wollner J, Pannek J. Initial experience with the treatment of neurogenic detrusor overactivity with a new beta-3 agonist (mirabegron) in patients with spinal cord injury. Spinal Cord. 2016;54(1):78–82. doi: 10.1038/sc.2015.195
  86. Stewart WF, Van Rooyen JB, Cundiff GW, et al. Prevalence and burden of overactive bladder in the United States. World J Urol. 2003;20(6):327–336. doi: 10.1007/s00345-002-0301-4
  87. Pranovich AA, Satardinova EE, Prashayeuv KI. Biomarkers of pathological aging of urothelia. Clinical Gerontology. 2018;(3–4):8–12. (In Russ.) doi: 10.26347/1607-2499201803-04008-012
  88. Shormanov IS, Solovyov AS, Tyuzikov IA, Kulikov SV. Anatomical, physiological and pathophysiological features of the lower urinary tract in gender and age aspects. Urology reports (St. Petersburg). 2021;11(3):241–256. (In Russ.) doi: 10.17816/uroved70710
  89. Shormanov IS, Kulikov SV, Solovyov AS. Features of compensatory and adaptive reactions of the vascular bed of the bladder of elderly and senile men with prostatic hyperplasia. Urology Reports (St. Petersburg). 2022;12(2):127–135 (In Russ.) doi: 10.17816/uroved108475
  90. Kay GG, Abou-Donia MB, Messer WS Jr, et al. Antimuscarinic drugs for overactive bladder and their potential effects on cognitive function in older patients. J Am Geriatr Soc. 2005;53(12):2195–2201. doi: 10.1111/j.1532-5415.2005.00537.x
  91. Nakagomi H, Mitsui T, Shimura H, et al. Mirabegron for overactive bladder in frail patients 80 years or over (HOKUTO study). BMC Urol. 2022;22(1):40. doi: 10.1186/s12894-022-00989-7
  92. Özcan C, Sancı A, Beyatlı M, et al. The efficiency and safety of mirabegron monotherapy for the treatment of urge incontinence in women aged >80 Years. Cureus. 2023;15(1):e33685. doi: 10.7759/cureus.33685

Supplementary files

Supplementary Files
Action
1. JATS XML
Download
2. Figure. Treatment of overactive bladder according to clinical guidelines

Download (34KB)
Indexing metadata

Copyright (c) 2023 Eco-Vector


 


Согласие на обработку персональных данных с помощью сервиса «Яндекс.Метрика»

1. Я (далее – «Пользователь» или «Субъект персональных данных»), осуществляя использование сайта https://journals.rcsi.science/ (далее – «Сайт»), подтверждая свою полную дееспособность даю согласие на обработку персональных данных с использованием средств автоматизации Оператору - федеральному государственному бюджетному учреждению «Российский центр научной информации» (РЦНИ), далее – «Оператор», расположенному по адресу: 119991, г. Москва, Ленинский просп., д.32А, со следующими условиями.

2. Категории обрабатываемых данных: файлы «cookies» (куки-файлы). Файлы «cookie» – это небольшой текстовый файл, который веб-сервер может хранить в браузере Пользователя. Данные файлы веб-сервер загружает на устройство Пользователя при посещении им Сайта. При каждом следующем посещении Пользователем Сайта «cookie» файлы отправляются на Сайт Оператора. Данные файлы позволяют Сайту распознавать устройство Пользователя. Содержимое такого файла может как относиться, так и не относиться к персональным данным, в зависимости от того, содержит ли такой файл персональные данные или содержит обезличенные технические данные.

3. Цель обработки персональных данных: анализ пользовательской активности с помощью сервиса «Яндекс.Метрика».

4. Категории субъектов персональных данных: все Пользователи Сайта, которые дали согласие на обработку файлов «cookie».

5. Способы обработки: сбор, запись, систематизация, накопление, хранение, уточнение (обновление, изменение), извлечение, использование, передача (доступ, предоставление), блокирование, удаление, уничтожение персональных данных.

6. Срок обработки и хранения: до получения от Субъекта персональных данных требования о прекращении обработки/отзыва согласия.

7. Способ отзыва: заявление об отзыве в письменном виде путём его направления на адрес электронной почты Оператора: info@rcsi.science или путем письменного обращения по юридическому адресу: 119991, г. Москва, Ленинский просп., д.32А

8. Субъект персональных данных вправе запретить своему оборудованию прием этих данных или ограничить прием этих данных. При отказе от получения таких данных или при ограничении приема данных некоторые функции Сайта могут работать некорректно. Субъект персональных данных обязуется сам настроить свое оборудование таким способом, чтобы оно обеспечивало адекватный его желаниям режим работы и уровень защиты данных файлов «cookie», Оператор не предоставляет технологических и правовых консультаций на темы подобного характера.

9. Порядок уничтожения персональных данных при достижении цели их обработки или при наступлении иных законных оснований определяется Оператором в соответствии с законодательством Российской Федерации.

10. Я согласен/согласна квалифицировать в качестве своей простой электронной подписи под настоящим Согласием и под Политикой обработки персональных данных выполнение мною следующего действия на сайте: https://journals.rcsi.science/ нажатие мною на интерфейсе с текстом: «Сайт использует сервис «Яндекс.Метрика» (который использует файлы «cookie») на элемент с текстом «Принять и продолжить».